Tevogen signs LoI to evaluate acquisition of contract research organization

Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with a distinguished global contract research organization. If consummated, the proposed transaction could expand Tevogen’s clinical development capabilities and could support the company’s evolution into a revenue-generating healthcare enterprise, it said. Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, stated, “The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally. We believe this combination of operational control and service revenue may strengthen earnings visibility, support a more capital-efficient growth model, and enhance patient affordability.” The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions. Tevogen is also actively considering other transactions with a focus on life sciences-related businesses; however, there can be no assurance that any such transaction will be consummated.